11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

Citi raised the firm’s price target on Insulet to $310 from $283 and keeps a Buy rating on the shares as part of a 2025 outlook for the U.S.

Insulet, an Acton medical device manufacturer, has been awarded $452 million in total damages by a federal jury.

Insulet Corporation’s PODD rapid progress with its strategic imperatives on Omnipod platform is poised to help it grow in the upcoming quarters. The largely untapped diabetes market also presents ...

Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Insulet (PODD – Research Report) today and set a price target of $305.00. The ...

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...